ClinicalTrials.gg
RecruitingNCT07832201Updated Nov 17, 2026

A Phase IV Clinical Trial of Influenza Vaccine (Split Virion), Inactivatedin (Anflu®) Pregnant Women (AnFLU-PREG)

A Phase 4 interventional study of Anflu® and Vaxigrip® in Influenza, sponsored by Sinovac Biotech Co., Ltd. Recruiting at 6 sites in China. Open to female participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Sinovac Biotech Co., Ltd · Phase 4, Interventional, and Prevention

Updated Nov 17, 2026Now RecruitingSite recruiting status changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 27 studies in Influenza, Human by Sinovac Biotech Co., Ltd — 2 open to participants now, 3 under way, none of them phase 3. Influenza, Human · Sinovac Biotech Co., Ltd.

Planned enrollment
19th of 25
150 · median 400
Started
2026
with 1 other
Phase 4
14 of 27
1 open now
Registered
26th of 27
by date

Among the 27 studies in Influenza, Human by Sinovac Biotech Co., Ltd, this one is the 19th largest by planned enrollment of the 25 interventional ones that give a count, is one of 2 that started in 2026, is one of 14 in phase 4, and was the 26th registered.

Influenza, Human

2,360 studies on the registry are indexed under Influenza, Human; 185 are open to participants now.

Browse Influenza, Human studies →

Open to participants now

2 of the 27 studies in Influenza, Human by Sinovac Biotech Co., Ltd are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 123 Influenza, Human studies recruiting now, 66 (54%) set no upper age limit and 47 (38%) stop at 75 or younger; 34 take children under 18; 68 take healthy volunteers.

This study: 18 Years to 45 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Influenza, Human by Sinovac Biotech Co., Ltd, or all of them as a file.
02

Study summary

A phase IV clinical trial of Influenza Vaccine (Split Virion), Inactivated (Anflu®) developed by Sinovac Biotech Co., Ltd will be conducted in pregnant women.

A total of 150 healthy pregnant women aged 18\~45 years at 22 to 34 weeks (+6 days) of pregnancy will be enrolled. All participants will be randomized to test group and control group in a ratio of 2:1 and receive one dose of vaccine (0.5 mL) of Sinovac Influenza Vaccine (Split Virion) , Inactivated (Anflu®) or Sanofi VAXIGRIP®, respectively.

Read the detailed description

A phase IV clinical trial of Influenza Vaccine (Split Virion), Inactivated (Anflu®) developed by Sinovac Biotech Co., Ltd will be conducted in Chinese pregnant women.

A total of 150 healthy pregnant women aged 18\~45 years at 22 to 34 weeks (+6 days) of pregnancy will be enrolled.The trial is a randomized, double-blind, positive controlled study to evaluate the immunogenicity and safety of Influenza Vaccine (Split Virion) ,Inactivated (Anflu®) manufactured by Sinovac. The active control vaccine is VAXIGRIP® manufactured by Sanofi.

For immunogenicity assessment, blood samples will be collected from participants prior to vaccination, 28 days post-vaccination, and at the end of pregnancy (at delivery) to evaluate antibody levels in pregnant women following influenza vaccination. Additionally, the cord blood samples will be collected at delivery to assess transplacental antibody transfer to the fetus. Antibodies will be tested using the hemagglutination-inhibition (HI) assay.

For safety assessment, any immediate adverse events within 30 minutes after vaccine administration, solicited local and systemic adverse events within 7 days and unsolicited adverse events within 28 days will be collected. Serious adverse events will be collected from the time of informed consent signature until 3 months after delivery (or until 3 months after the event if pregnancy termination occurs). Pregnancy and neonatal outcomes will be collected by medical record review .

03

Conditions studied

  • Influenza

Browse trials for

Keywords

  • pregnant women
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy pregnant women aged 18 to 45 years (inclusive) with stable health status, at 22 to 34 weeks (+6 days) of gestation. Gestational age is determined based on early ultrasound examination, or based on the last menstrual period if early ultrasound is unavailable.
  2. Participants are able to understand and sign the form voluntarily;
  3. Participants are willing and able to adhere to visit schedules and maintain accessible contact throughout the study period;
  4. Participants should provide verifiable identification;
  5. Have a singleton pregnancy;
  6. Have normal non-invasive prenatal DNA test and systematic ultrasound results during the current pregnancy; normal amniocentesis results are required if the test has been performed.

Exclusion criteria

Exclusion Criteria:

  1. Have a history of two or more preterm deliveries (delivery before 37 weeks of gestation), previous infants with low birth weight (birth weight \<2500 g), or a history of neonatal asphyxia or neonatal neurological damage;
  2. Have a history of multiple unexplained spontaneous abortions;
  3. Have received any influenza vaccine or the influenza vaccine for the current influenza season within 6 months prior to enrollment, or plan to receive influenza vaccination during the study period.
  4. Have suffered from seasonal influenza within 6 months prior to enrollment.
  5. Have a history of Guillain-Barré syndrome within 6 weeks after previous influenza vaccination.
  6. Have allergic reactions or other severe adverse reactions to any influenza vaccine or its components.
  7. Have severe diseases or immunodeficiency diseases (including but not limited to active systemic lupus erythematosus, rheumatoid arthritis, asplenia, functional asplenia, and infection) and are judged unsuitable for vaccination by the investigator.
  8. Abnormal coagulation function (such as coagulation factor deficiency, coagulation disorders or abnormalities).
  9. Have severe chronic diseases (including but not limited to cardiovascular diseases, partial liver diseases, renal diseases or malignant tumors) that may interfere with the study as judged by the investigator.
  10. Have a current or previous history of severe neurological diseases (epilepsy, convulsions) or psychiatric disorders, or have a family history of psychiatric disorders.
  11. Received (adult prednisone ≥20 mg/day or equivalent) or other for ≥14 days, or cytotoxic therapy within 6 months prior to vaccination, or plan to receive such therapy during the study period.
  12. Received immunoglobulins or other blood products within 3 months prior to vaccination, or plan to receive such products during the study period.
  13. Received any vaccine within 28 days prior to study vaccination, or plan to receive any vaccine within 28 days after study vaccination.
  14. Have enrolled in other clinical trials of drugs or vaccines during the follow-up period, or plan to receive investigational drugs or vaccines during the study period.
  15. Have acute diseases or acute exacerbation of chronic diseases within 7 days before vaccination.
  16. Have fever on the scheduled vaccination day with an axillary temperature ≥37.3 °C before vaccination.
  17. Have abnormal laboratory findings as judged by the investigator, or meet any of the following laboratory criteria: a) White blood cell count >15.0×10\^9/L; b) Neutrophil percentage >85%; c) (ALT) or aspartate aminotransferase (AST) >2 times the (2×ULN); d) Total >2 times the upper limit of normal (2×ULN).
  18. Any other factors which are unsuitable for participation in the clinical trial as judged by the investigator.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    Test Group

    100 participants will receive one dose of vaccine (0.5 mL) of Sinovac Influenza Vaccine (Split Virion) Inactivated (Anflu®) . Route of administration is intramuscular injection at deltoid muscle of upper arm.Immunization schedule is 1 dose

    Biological: Anflu®

  • Active comparator
    Control Group

    50 participants will receive one dose of vaccine (0.5 mL) of VAXIGRIP® manufactured by Sanofi. Route of administration is intramuscular injection at deltoid muscle of upper arm.Immunization schedule is 1 dose

    Biological: Vaxigrip®

Interventions

  • BiologicalAnflu®

    Participants will receive one dose of Sinovac Anflu® .

  • BiologicalVaxigrip®

    Participants will receive one dose of Sanofi Vaxigrip®.

06

What researchers measure

Primary outcomes

  1. The seroconversion rates (SCRs) of hemagglutination inhibition (HI) antibodies at day 28 ,as measured by HAI assay for vaccine-matched influenza A and B

    Influenza A included H1N1 and H3N2 and influenza B strains included Victoria-lineage. Seroconversion is defined as either a baseline HI titer \<1:10 and a post-vaccination titer ≥1:40 or a baseline HI titer ≥1:10 and a minimum 4-fold rise in post-vaccination HI antibody titer.

    Time frame: 28 days after vaccination

  2. Incidence of adverse reactions within 28 days after vaccination

    Incidence of adverse reactions within 28 days after vaccination. Adverse reactions include solicited and unsolicited adverse reactions. Solicited local (injection site) symptoms: pain, swelling, erythema, induration, pruritus; Solicited systemic (non-injection site) symptoms: fever (axillary temperature), fatigue, myalgia, headache, hypersensitivity reaction.

    Time frame: 28 days after vaccination

Secondary outcomes

  1. The seroprotection rates (SPRs) of HI antibodies at day 28 ,as measured by HAI assay for vaccine-matched influenza A and B

    Influenza A included H1N1 and H3N2 and influenza B strains included Victoria-lineage. Seroprotection is defined as an HI titer ≥1: 40.

    Time frame: 28 days after vaccination

  2. The geometric mean titers (GMTs) of HI antibodies at day 28 ,as measured by HAI assay for vaccine-matched influenza A and B

    Influenza A included H1N1 and H3N2 and influenza B strains included Victoria-lineage. Log-transformed post-vaccination HI antibody titer will be the dependent variable, with treatment group as fixed effect and log-transformed pre-vaccination HI antibody titer as covariate. Least-squares mean differences with two-sided 95% CIs will be estimated and back-transformed via exponentiation to derive adjusted GMT ratios (experimental vs control) and corresponding two-sided 95% CIs.

    Time frame: 28 days after vaccination

  3. The geometric mean fold rises (GMFRs) of HI antibodies at day 28 ,as measured by HAI assay for vaccine-matched influenza A and B

    Influenza A included H1N1 and H3N2 and influenza B strains included Victoria-lineage. Geometric mean of antibody fold-rise with two-sided 95% CI will be calculated , along with the geometric mean ratio and its corresponding two-sided 95% CI.

    Time frame: 28 days after vaccination

  4. The SCRs of HI antibodies at delivery, as measured by HAI assay for vaccine-matched influenza A and B

    Influenza A included H1N1 and H3N2 and influenza B strains included Victoria-lineage. Seroconversion is defined as either a baseline HI titer \<1:10 and a post-vaccination titer ≥1:40 or a baseline HI titer ≥1:10 and a minimum 4-fold rise in post-vaccination HI antibody titer.

    Time frame: At the date of delivery , estimated to be 6-18 weeks after randomization.

  5. The SPRs of HI antibodies at delivery ,as measured by HAI assay for vaccine-matched influenza A and B

    Influenza A included H1N1 and H3N2 and influenza B strains included Victoria-lineage. Seroprotection is defined as an HI titer ≥1: 40.

    Time frame: At the date of delivery , estimated to be 6-18 weeks after randomization.

  6. The GMTs of HI antibodies at delivery,as measured by HAI assay for vaccine-matched influenza A and B

    Influenza A included H1N1 and H3N2 and influenza B strains included Victoria-lineage. Log-transformed post-vaccination HI antibody titer will be the dependent variable, with treatment group as fixed effect and log-transformed pre-vaccination HI antibody titer as covariate. Least-squares mean differences with two-sided 95% CIs will be estimated and back-transformed via exponentiation to derive adjusted GMT ratios (experimental vs control) and corresponding two-sided 95% CIs.

    Time frame: At the date of delivery , estimated to be 6-18 weeks after randomization.

  7. The GMFRs of HI antibodies at delivery,as measured by HAI assay for vaccine-matched influenza A and B

    Influenza A included H1N1 and H3N2 and influenza B strains included Victoria-lineage. Geometric mean of antibody fold-rise with two-sided 95% CI will be calculated , along with the geometric mean ratio and its corresponding two-sided 95% CI.

    Time frame: At the date of delivery , estimated to be 6-18 weeks after randomization.

  8. The SPRs of HI antibodies in cord blood at delivery ,as measured by HAI assay for vaccine-matched influenza A and B

    Influenza A included H1N1 and H3N2 and influenza B strains included Victoria-lineage. Seroprotection is defined as an HI titer ≥1: 40.

    Time frame: At the date of delivery, estimated to be 6-18 weeks after randomization

  9. The GMTs of HI antibodies in cord blood at delivery, as measured by HAI assay for vaccine-matched influenza A and B

    Influenza A included H1N1 and H3N2 and influenza B strains included Victoria-lineage. Log-transformed post-vaccination HI antibody titer will be the dependent variable, with treatment group as fixed effect and log-transformed pre-vaccination HI antibody titer as covariate. Least-squares mean differences with two-sided 95% CIs will be estimated and back-transformed via exponentiation to derive adjusted GMT ratios (experimental vs control) and corresponding two-sided 95% CIs.

    Time frame: At the date of delivery, estimated to be 6-18 weeks after randomization

  10. Incidence of serious adverse events from vaccination through 3 months after delivery.

    Serious adverse events within 3 months after delivery.

    Time frame: From vaccination to 3 months after delivery.

  11. Pregnancy outcomes

    Pregnancy outcomes: term birth, preterm birth, elective termination of pregnancy, fetal death, and gestational complications, etc.

    Time frame: At the date of delivery, estimated to be 6-18 weeks after randomization

  12. Neonatal birth outcomes

    Birth outcomes: normal status, low birth weight, congenital malformations, neonatal NICU admission, and neonatal death, etc.

    Time frame: 3 months after delivery

07

Study locations

5 of 6 sites recruiting
  • Hunan Provincial Maternal and Child Health Care Hospital
    Changsha, China
    Recruiting
    • Tang Yabing · Contact
  • Chengdu Women's and Children's Central Hospital
    Chengdu, China
    Recruiting
    • Lai Fan · Contact
  • The First Affiliated Hospital of Chongqing Medical University
    Chongqing, China
    Recruiting
    • Qi Hongbo · Contact
  • Nanfang Hospital, Southern Medical University
    Guangzhou, China
    Recruiting
    • Huang Liping · Contact
  • Nanjing Drum Tower Hospita
    Nanjing, China
    Recruiting
    • Li Jie · Contact
  • Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
    Wuhan, China
    Not yet recruiting
    • Feng Ling · Contact
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Feb 2027, 4 months later.

Of 37 industry-sponsored phase 4 interventional studies under Influenza, Human, half reached primary completion within 3 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 6. This study's planned 4 months is above that.

Counting every sponsor, half of 138 studies reached it within 14 months; a quarter within 3 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 28, 2026
First posted
Sep 21, 2026
StartEst.
Oct 20, 2026
Primary completionEst.
Feb 2027
CompletionEst.
Apr 2027
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 17, 2026
Sites
6 sites changed recruiting status (5 now recruiting, 1 now not yet recruiting)
Show 6 sites
  • Hunan Provincial Maternal and Child Health Care Hospital · Changsha, Chinano status→Recruiting
  • Chengdu Women's and Children's Central Hospital · Chengdu, Chinano status→Recruiting
  • The First Affiliated Hospital of Chongqing Medical University · Chongqing, Chinano status→Recruiting
  • Nanfang Hospital, Southern Medical University · Guangzhou, Chinano status→Recruiting
  • Nanjing Drum Tower Hospita · Nanjing, Chinano status→Recruiting
  • Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Chinano status→Not yet recruiting
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Not yet recruiting→Recruiting
    6 sites changed recruiting status (5 now recruiting, 1 now not yet recruiting)
    Show 6 sites
    • Hunan Provincial Maternal and Child Health Care Hospital · Changsha, Chinano status→Recruiting
    • Chengdu Women's and Children's Central Hospital · Chengdu, Chinano status→Recruiting
    • The First Affiliated Hospital of Chongqing Medical University · Chongqing, Chinano status→Recruiting
    • Nanfang Hospital, Southern Medical University · Guangzhou, Chinano status→Recruiting
    • Nanjing Drum Tower Hospita · Nanjing, Chinano status→Recruiting
    • Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Chinano status→Not yet recruiting
    + 1 other change: date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07832201
Responsible party
Sponsor
First posted
Sep 21, 2026
Start date
Oct 20, 2026 (estimated)
Primary completion
Feb 2027 (estimated)
Completion
Apr 2027 (estimated)
Last update
Nov 17, 2026

Study contacts

Qi Hongbo
Contact
qihongbo@cqmu.edu.cn
13808376116
Qi Hongbo
principal investigator · First Affiliated Hospital of Chongqing Medical University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion